Compare Pfizer Inc (PFE) vs Tapestry, Inc. (TPR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Pfizer Inc vs Tapestry, Inc. — how do they compare? Pfizer Inc trades at $27.83 (market cap $159.59B), while Tapestry, Inc. trades at $115.82 (market cap $22.62B). The key difference: Pfizer Inc is far larger — about 7.1× Tapestry, Inc.'s market cap, and Pfizer Inc pays the higher dividend (6.14%). Which is the better fit depends on your goals — on Pluang, investors hold Pfizer Inc for 158 Days and Tapestry, Inc. for 70 Days on average.
| PFE | TPR | |
|---|---|---|
Market Cap | $159.59B | $22.62B |
Volume | 30,937,010 | 2,093,865 |
Sector | Health | Consumer Cyclical |
52-Week High | $29.02 | $164.78 |
52-Week Low | $23.67 | $98.81 |
Typical Hold Time | 158 Days | 70 Days |
Enterprise Value | $211.09B | $25.42B |
Dividend Yield | 6.14% | 1.63% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
TPR trades at $113.39, down 2.86% today, with a bearish technical signal and neutral oscillators. The stock shows strong profitability with a 19.09% net income margin and 197.14% ROE, but net income fell sharply in 2025. Recent earnings beats and a $0.46 dividend highlight operational strength, while cash flow volatility and high debt-to-asset ratios pose concerns. Analyst consensus is strongly bullish with a $174.64 price target.
Outlook remains positive driven by international growth and margin expansion targets, but risks include execution challenges at Kate Spade, tariff pressures, and volatile cash flows. The stock offers value with a reasonable P/E of 15.6, though current price weakness near support at $113 may present a buying opportunity for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →About Tapestry, Inc.
Coach, Kate Spade, and Stuart Weitzman are the fashion and accessory brands that comprise Tapestry. The firm's products are sold through about 1,400 company-operated stores, wholesale channels, and e-commerce in North America (67% of fiscal 2022 sales), Europe, Asia (28% of fiscal 2022 sales), and elsewhere. Coach (74% of fiscal 2022 sales) is best known for affordable luxury leather products. Kate Spade (22% of fiscal 2022 sales) is known for colorful patterns and graphics. Women's handbags and accessories produced 69% of Tapestry's sales in fiscal 2022. Stuart Weitzman, Tapestry's smallest brand, generates nearly all its revenue from women's footwear.
Read more on TPR →
